Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 6/20 | 0.73 |
| ▸ | TAS1R1 | Q7RTX1 | 6/20 | 0.73 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5909489 | 1.00 | TAS1R3 (0.73) | TAS1R3TAS1R1HTTLMNAKMT2A | |
| SCHEMBL703277 | 0.85 | TAS1R3 (1.00) | TAS1R3TAS1R1HTTLMNAKMT2A | |
| SCHEMBL703278 | 0.85 | TAS1R3 (1.00) | TAS1R3TAS1R1HTTLMNAKMT2A | |
| SCHEMBL5909418 | 0.84 | TAS1R3 (0.70) | TAS1R3TAS1R1HTTLMNAKMT2A | |
| SCHEMBL5909421 | 0.84 | TAS1R3 (0.70) | TAS1R3TAS1R1HTTLMNAKMT2A | |
| SCHEMBL13988502 | 0.83 | TAS1R3 (0.69) | TAS1R3TAS1R1HTTLMNAKMT2A | |
| SCHEMBL5909220 | 0.83 | HTT (0.67) | TAS1R3TAS1R1HTTLMNAKMT2A | |
| SCHEMBL5909218 | 0.83 | HTT (0.67) | TAS1R3TAS1R1HTTLMNAKMT2A | |
| SCHEMBL5909221 | 0.83 | HTT (0.67) | TAS1R3TAS1R1HTTLMNAKMT2A | |
| SCHEMBL6572555 | 0.82 | LMNA (0.82) | TAS1R3TAS1R1HTTLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060194801-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | EVOTEC AG (DE) | 2006-08-31 | — | — | US | claimed |
| US-20080312237-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS, INC. | 2008-12-18 | — | — | US | disclosed |
| US-20080312237-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS, INC. | 2008-12-18 | — | — | US | disclosed |
| US-7432281-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432281-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194801-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | TRPV1, TRPA1, TRPV2 | TAS1R3 1338/4885TAS1R1 1582/4885HTT 3330/4885 |
| US-20080312237-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | TRPV1, TRPA1, TRPV2 | TAS1R3 1338/4885TAS1R1 1582/4885HTT 3330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.